ArticleAmerican journal of public health2018
Mortality Among Confirmed Lassa Fever Cases During the 2015-2016 Outbreak in Nigeria.
Article in American journal of public health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Clinical Outcomes of Severe Lassa Fever in West Africa: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2025Pooled it
- Lassa fever in West Africa: a systematic review and meta-analysis of attack rates, case fatality rates and risk factors.BMC public health · 2025Pooled it
- Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished StudiesEmerging infectious diseases · 2022Pooled it
- Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design.PLoS neglected tropical diseases · 2021Pooled it
- Systematic review and meta-analysis of the epidemiology of Lassa virus in humans, rodents and other mammals in sub-Saharan Africa.PLoS neglected tropical diseases · 2020Pooled it
- Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics.Emerging infectious diseases · 2025Trial
- Evaluation of candidate reference materials for the harmonization of Lassa fever serology.Emerging microbes & infections · 2026Article
- Lassa Virus-A Persistent and Evolving Threat.Microorganisms · 2026Review
- Article
- Predictors of Acute Kidney Injury and In-Hospital Mortality in Patients With RT-PCR Confirmed Lassa Fever in Southwest Nigeria.Open forum infectious diseases · 2026Article
- Identification of Factors Contributing to Pathogenic Variability Among Lassa Virus Strains Using the Guinea Pig Model and Reverse Genetics.The Journal of infectious diseases · 2025Article
- The Biological Characteristics and Mouse Model of Lassa Virus From the First Imported Case in China.MedComm · 2025Article
- Flunarizine as a Candidate for Drug Repurposing Against Human Pathogenic Mammarenaviruses.Viruses · 2025Article
- U-73122, a phospholipase C inhibitor, impairs lymphocytic choriomeningitis virus virion infectivity.The Journal of general virology · 2024Article
- The DNA-based Lassa vaccine INO-4500 confers durable protective efficacy in cynomolgus macaques against lethal Lassa fever.Communications medicine · 2024Article
- A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs.NPJ vaccines · 2024Article
- Lassa virus persistence with high viral titers following experimental infection in its natural reservoir host, Mastomys natalensis.Nature communications · 2024Article
- An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.Journal of virology · 2024Article
- Unraveling factors responsible for pathogenic differences in Lassa virus strains.bioRxiv : the preprint server for biology · 2024Article
- Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus.Cell reports. Medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine factors associated with mortality among confirmed Lassa fever cases.
methodsWe reviewed line lists and clinical records of laboratory-confirmed cases of Lassa fever during the 2016 outbreak in Nigeria to determine factors associated with mortality. We activated an incident command system to coordinate response.
resultsWe documented 47 cases, 28 of whom died (case fatality rate [CFR] = 59.6%; mean age 31.4 years; SD = ±18.4 years). The youngest and the oldest were the most likely to die, with 100% mortality in those aged 5 years or younger and those aged 55 years or older. Patients who commenced ribavirin were more likely to survive (odds ratio [OR] = 0.1; 95% confidence interval [CI] = 0.03, 0.50). Fatality rates went from 100% (wave 1) through 69% (wave 2) to 31% (wave 3; χ
conclusionsEffective, coordinated response reduces mortality from public health events. Attention to vulnerable groups during disasters is essential. Public Health Implications. Activating an incident command system improves the outcome of disasters in resource-constrained settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.